Introduction
Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related death worldwide [
1]. Currently, fluorouracil (5-Fu)-based chemotherapy is one of the most frequently used therapeutic strategies for advanced CRC patients, and its mechanism of action is direct or indirect induction of DNA damage response (DDR) pathways [
2]. Although the majority of patients with advanced CRC are initially responsive to the 5-Fu-based combination chemotherapy, tumors frequently recur due to drug resistance. Immune checkpoint inhibitors have recently shown promise in a limited subset of patients as a treatment for CRC [
3]. Therefore, further elucidating the mechanisms of DDR and chemoresistance in CRC and improving the efficacy of chemotherapy have important clinical significance.
DNA-damage checkpoints are signaling cascades that either trigger cell cycle arrest, which allows time for DNA repair or induce apoptotic cell death [
4]. Transduction of the DDR signal, such as that induced by 5-Fu, is often carried out by a set of conserved checkpoint protein kinases, including ataxia telangiectasia mutated (ATM), ATM- and Rad3-related (ATR) proteins, and the downstream checkpoint kinases CHK2 and CHK1. Phosphorylation of CHK1 at S317 and S345 by the ATR kinase is required for its activation in response to DNA damage [
4]. CHK1 is upregulated in multiple human cancers, including CRC, and its overexpression and/or hyperactivation is linked to chemo- and radiotherapy resistance [
5‐
10]. CHK1-targeted therapy selectively eliminates replication-stressed, p53-deficient, and hyperdiploid colorectal cancer stem cells [
11,
12]. Accumulating evidence has shown that CHK1 ubiquitination is critical for its stability, subcellular localization, and phosphorylation. Furthermore, K48-linked ubiquitination downregulates CHK1 expression, whereas K63-linked ubiquitination upregulates CHK1 activity [
13‐
15]. However, how the DDR triggers the ubiquitination-dependent activation of CHK1 to promote CRC cell survival remains elusive.
Tumor necrosis factor receptor-associated factor 4 (TRAF4, also known as RING finger protein 83 or RNF83) is emerging as a critical regulator for cancer cell proliferation, survival, and metastasis [
16‐
18]. TRAF4 promotes the invasion of CRC cells by regulating Wnt/β-catenin signaling [
19,
20]. Recent reports suggest the N-terminal RING finger domain of TRAF4 has E3 ligase activity that ubiquitinates AKT, SMURF2, and TrkA to promote tumor growth and metastasis [
16‐
18]. Due to the critical role of TRAF4 in tumorigenesis and its druggable enzymatic activity, identification of novel TRAF4 substrates will be helpful for developing new cancer treatment strategies.
Here, we identified TRAF4 as an E3 ligase that ubiquitinates CHK1. During DDR, TRAF4 ubiquitinates CHK1, which is a prerequisite for CHK1 chromatin association and subsequent phosphorylation and activation by ATR in CRC cells. The absence of TRAF4 sensitizes CRC cells to chemotherapeutic agents in a CHK1 ubiquitination- and activation-dependent manner, suggesting that CHK1 ubiquitination by TRAF4 is a potential therapeutic target to overcome CRC chemoresistance.
Materials And methods
Cell culture and reagents
HT29, SW620, HCT-8, FHC, HeLa, U2OS, A549, H1975, and 293T cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured at 37 °C in a humidified incubator with 5% CO2 according to ATCC protocols. All cell lines were routinely checked for mycoplasma and tested cytogenetically to ensure their authentication. Chemical reagents, including Tris, NaCl, SDS, and dimethyl sulfoxide (DMSO), were purchased from Sigma-Aldrich (St. Louis, MO, USA). Oxaliplatin (cat. #S1224), 5-Fu (cat. #S1209), irinotecan (cat. #S2217), cisplatin (cat. #S1166), pemetrexed (cat. #S1135), gemcitabine (cat. #S1714), VE-821 (cat. #S8007), AZ20 (cat. #S7050), and prexasertib were obtained from Selleck Chemicals (Houston, TX, USA). Lipofectamine™ 2000 (cat. #11668019, Thermo Fisher Scientific) transfection reagent was used for transient transfection experiments following the manufacturer’s instruction. Ctrl siRNA (cat. #sc-93314), UbcH6 siRNA (cat. #sc-61744), BTG3 siRNA (cat. #sc-43644), and ATR siRNA (cat. #sc-29763) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Three independent experiments were completed for each cell line, treatment, and time point, as indicated.
Immunoblotting (IB) and immunoprecipitation (IP)
Whole-cell lysates were extracted with RIPA buffer (cat. #89900, Thermo Fisher Scientific) supplemented with phosphatase inhibitors (cat. #78428, Thermo Fisher Scientific). The lysates were sonicated and centrifuged at 12000×
g for 15 min at 4 °C. The BCA Assay Reagent (cat. #23228, Thermo Fisher Scientific) was used to determine protein concentration. For co-immunoprecipitation (co-IP) assays, cells were lysed with IP Lysis Buffer (cat. #87787, Thermo Fisher Scientific). IB and co-IP were performed as previously described [
16]. All antibodies for IB analysis were diluted in phosphate-buffered saline (PBS) buffer with 5% non-fat milk. Antibodies against Bax (cat. #5023; IB, 1:1000), Bik (cat. #4592; IB, 1:1000), Bim (cat. #2933; IB, 1:1000), Bid (cat. #2002; IB, 1:1000), Bak (cat. #12105; IB, 1:1000), survivin (cat. #2808; IB, 1:1000), Bcl-2 (cat. #4223; IB, 1:1000), Bcl-xL (cat. #2764; IB, 1:1000), Mcl-1 (cat. #5453; IB, 1:1000), γ-H2AX (cat. #9718; IB, 1:4000), α-tubulin (cat. #2144; IB, 1:10000), ubiquitin (cat. #3936; IB, 1:1000), cleaved-caspase 3 (cat. #9664; IB, 1:2000), cleaved-PARP (cat. #5625; IB, 1:2000), p-(Ser/Thr) ATM/ATR substrate (cat. #2851; IB, 1:1000), p-ATR (S428) (cat. # 2853; IB, 1:1000), p-ATR (Thr1989) (cat. #30632; IB, 1:1000), ATR (cat. # 13934; IB, 1:1000), p-CHK1 (S317) (cat. #12302; IB, 1:1000), p-CHK1 (S345) (cat. #2348; IB, 1:1000), CHK1 (cat. #2360; IB, 1:1000; IP, 1:200), p-CDC25C (Ser216) (cat. #4901; IB, 1:1000), CDC25C (cat. #4688; IB, 1:1000), GST tag (cat. #2624; IB, 1:5000; IP, 1:200), K63-linkage-specific polyubiquitin (cat. #12930; IB, 1:1000), rabbit IgG HRP (cat. #7074; IB, 1:10000), and mouse IgG HRP (cat. #7076; IB, 1:10,000) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibodies against β-actin (cat. #A5316; IB, 1:10000), TRAF4 (cat. #MABC985; IB, 1:4000; IP, 1:200), Flag tag (cat. #F3165; IB, 1:10000; IP, 1:400), and Flag–HRP (cat. #A8592; IB, 1:20000) were from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against HA tag (cat. #ab18181; IB, 1:5000; IP, 1:200) and His tag (cat. #ab18184; IB, 1:5000) were purchased from Abcam (Cambridge, UK). GFP-tag (cat. #TA150032; IB, 1:4000; IP, 1:400) antibody was obtained from OriGene (Rockville, MD, USA). Rabbit anti-TRAF4 (cat. #A302-840A; IB, 1:1000; IP, 1:200) and anti-CHK1 (cat. #A300-298A; IB, 1:1000; IP, 1:200) antibodies were purchased from Bethyl Laboratories (Montgomery, TX, USA). Antibody conjugates were visualized by chemiluminescence (cat. #34076, Thermo Fisher Scientific).
Plasmid construction
Flag–TRAF4 (cat. #RC200345), GFP–TRAF4 (cat. #RC200345L4), Flag–Chk1 (cat. #RC205094), and GFP–Chk1 (cat. #RC225807L4) were obtained from OriGene. pCDNA3–HA–Akt1 (cat. #73408) was obtained from Addgene (Watertown, MA, USA). His–Ub was a gift from Jianneng Li at Lerner Research Institute, Cleveland Clinic. Flag–Chk1 (DM-N), Flag–Chk1 (DM-C), Flag–TRAF4 (DM-RING), Flag–TRAF4 (DM-Inter), and Flag–TRAF4 (DM-TRAF), Flag–GFP–TRAF4 (C18A), Flag–GFP–TRAF4 (T192A), Flag–GFP-–TRAF4 (T192D), His–Ub (K6, K11, K27,K29, K33, K48, and K63), His–Ub (K48R), His–Ub (K63R), and Flag–Chk1 (S317/345A, K38R, K54R, K145R, K132R, K233R, K244R, K404R, K444R, K451R, and K456/458R) mutants were developed using the Q5 Site-Directed Mutagenesis Kit (cat. #E0554S, NEB) following the manufacturer’s protocol. All mutant constructs were generated using mutagenesis PCR were verified by Sanger DNA sequencing.
To generate CRISPR-Cas9-based
TRAF4 and
Chk1 knockout constructs, we cloned the annealed single-guide RNAs (sgRNAs) into the Bsm BI-digested lentiCRISPR V2 vector (cat. #52961, Addgene). The sgRNAs were from the Human CRISPR Knockout Pooled Library (GeCKO v2) [
21] and are listed as follows: sg
TRAF4#1 forward, 5′-AGCCACAAAACTCGCACTTG-3′; reverse, 5′-CAAGTGCGAGTTTTGTGGCT-3′; sg
TRAF4#2 forward, 5′-CTCTGCCCATTCAAAGACTC-3′; reverse, 5′-GAGTCTTTGAATGGGCAGAG-3′; sg
Chk1#1 forward, 5′-AGTCATGGCAGTGCCCTTTG-3′; reverse, 5′-CAAAGGGCACTGCCATGACT-3′; sg
Chk1#2 forward, 5′-GAGATTCTTCCATCAACTCA-3′; reverse, 5′-TGAGTTGATGGAAGAATCTC-3′. The control or stable knockout cells were generated by transient transfection of sgRNA-inserted CRISPR-Cas9 plasmids and selected with 2 μg/ml puromycin for 2–3 weeks.
Cell proliferation assays
Cells were seeded at a density of 3 × 103 cells/well in 96-well plates. After overnight incubation, fresh medium containing different doses of chemotherapeutic agents was added, and the plates were maintained for 0, 24, 48, or 72 h. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) reagent (cat. #G3581, Promega) was used for cell viability assays. Cell proliferation was measured using the 5-ethynyl-2′-deoxyuridine (EdU) assay. Briefly, cells were seeded at a density of 1 × 104 cells in chamber slides (cat. #PEZGS0416, Millipore) and cultured overnight. Cells were then treated with 10 μM 5-Fu for 24 h. Next, 10 μM EdU (cat. #C10339, Thermo Fisher Scientific) was added to the culture medium, which was incubated for an additional 12 or 24 h. Cells were fixed and stained following the manufacturer’s instructions.
Anchorage-independent cell growth assay
The soft-agar colony formation assay was performed as previously described [
16]. Briefly, CRC cells were treated with chemotherapeutic agents or treated for 24 h, suspended (1 × 10
4 cells per well) in 1 mL of 0.3% agar with Eagle’s basal medium containing 10% FBS, and overlaid into six-well plates containing a 0.6% agar base. The cultures were maintained at 37 °C in a 5% CO
2 incubator, and the colonies were counted at 2 weeks.
Cells were treated with chemotherapeutic agents or their vehicle control for 24 h and seeded into a 6-cm plate (300 cells/well). Cells were maintained for 2 weeks at 37 °C in a 5% CO2 incubator. Colonies were fixed with 4% paraformaldehyde, stained with 0.5% crystal violet, and counted under a microscope. Three independent experiments were performed as indicated.
In vitro kinase assay
For the CHK1 IP/kinase assay, stable HT29 cells were treated with 5-Fu or UV light and lysed in IP buffer containing protease and phosphatase inhibitors. CHK1 was immunoprecipitated from cell lysates with an anti-CHK1 antibody (cat. #A300-298A, Bethyl Laboratories) at 4 °C for 4 h and washed twice in IP buffer and twice in 1× kinase buffer (cat. #9802, Cell Signaling Technology, Inc.). The recombinant GST–CDC25C protein (1 μg) was mixed with the immunoprecipitated CHK1 in a 20 μL reaction and incubated with 100 μM ATP in 1× kinase buffer at 30 °C for 30 min. Protein phosphorylation was examined by IB.
Mass spectrometry
293T cells stably expressing Flag–CHK1 were lysed in an IP buffer containing protease and phosphatase inhibitors. IP was performed overnight at 4 °C with the whole-cell lysates using the Flag-tag antibody (cat. #F3165, Sigma-Aldrich) or normal mouse IgG (cat. #5415, Cell Signaling Technology). The IP proteins were resolved by SDS-PAGE, followed by Coomassie blue staining. The desired proteins were then digested and subjected to LC-MS at the Cleveland Clinic Proteomics Core. The peptides were analyzed using all collected collision-induced dissociation (CID) spectra and the search programs Sequest and Mascot. Protein and peptide identifications were validated using the program Scaffold.
In vivo ubiquitination assay
Cells were lysed with a lysis buffer (6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 5 mM imidazole, and 10 mM β-mercaptoethanol) supplemented with protease inhibitors and 10 mM N-ethylmaleimide (NEM, cat. #S3692, Selleck Chemicals). After sonication and centrifugation, the supernatant was incubated at room temperature for 4 h with 40 μL Ni-NTA-agarose beads (cat. #30210, Qiagen Inc.). The beads were centrifuged and washed sequentially with five buffers: (A) 6 M guanidine-HCl, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0, and 5 mM imidazole plus 10 mM β-mercaptoethanol; (B) 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 8.0, 10 mM imidazole, and 10 mM β-mercaptoethanol plus 0.1% Triton X-100; (C) 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 6.3, 10 mM β-mercaptoethanol, and 20 mM imidazole plus 0.2% Triton X-100; (D) 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 6.3, 10 mM β-mercaptoethanol, and 10 mM imidazole plus 0.1% Triton X-100; and (E) 8 M urea, 0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris/HCl, pH 6.3, 10 mM β-mercaptoethanol, 10 mM imidazole plus 0.05% Triton X-100. After the last wash, the beads were boiled with 2× SDS sample-loading buffer containing 200 mM imidazole, and the supernatant was separated by SDS-PAGE, followed by IB.
Cells were lysed with a modified RIPA buffer (20 mM NAP, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 1% SDS) supplemented with protease inhibitors (cat. #78430, Thermo Fisher Scientific) and 10 mM NEM. After sonication, the lysates were boiled at 95 °C for 15 min, diluted with RIPA buffer containing 0.1% SDS, then centrifuged at 1.6 × 104×g for 10 min at 4 °C. The supernatant was incubated overnight at 4 °C with the primary antibodies and 40 μL protein A-Sepharose beads. After washing with RIPA buffer, the beads were boiled with 2× SDS sample-loading buffer to elute the bound protein. The eluted protein was then separated by SDS-PAGE, followed by IB. The Chromatin Extraction Kit (ab117152, Abcam) was used for chromatin and non-chromatin fractions extraction following the standard instruction.
In vitro ubiquitination assay
The in vitro ubiquitination assay was performed as previously described [
17]. Briefly, Flag–TRAF4, Flag–TRAF4 (DM-RING), and Flag–TRAF4 (C18A) were expressed in 293T cells, immunoprecipitated with anti-Flag antibody, and eluted with Flag peptide. Flag–TRAF4, Flag–TRAF4 (DM-RING), or Flag–TRAF4 (C18A) protein along with GST–CHK1 protein (cat. #14-346, Millipore) were incubated with 40 nM Ube1 (E1), 0.7 μM UbcH6 (E2), and 10 μM ubiquitin for 3 h at 37 °C in reaction buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl
2, 1 mM DTT, and 2 mM ATP). After incubation, the protein mixtures were diluted with RIPA buffer and immunoprecipitated overnight with the anti-CHK1 antibody at 4 °C. CHK1 ubiquitination was then analyzed by IB.
Xenograft mouse model
All procedures for the xenograft mouse models were conducted under protocols approved by our Institutional Animal Care and Use Committee (IACUC). Xenograft tumors were established by subcutaneous injection of stable HT29, SW620, and H1975 cells (1 × 106) into the right flank of 6-week-old NSG mice (The Jackson Laboratory, Bar Harbor, ME, USA). Tumors were measured with calipers every 2days, and mice received one of the following treatments by intraperitoneal injection when tumors reached a volume of 100 mm3: (1) vehicle, every 4 days; (2) 5-Fu, 50 mg/kg every 4 days; (3) oxaliplatin, 5 mg/kg every 4 days; (4) irinotecan, 10 mg/kg every 4 days; (5) cisplatin, 5 mg/kg every 4 days; or subcutaneous injection of (6) prexasertib, 16 mg/kg twice every 7 days; (7) the combination of prexasertib, 16 mg/kg twice every 7 days, and 5-Fu, 50 mg/kg every 4 days. Tumor volume was calculated with the following formula: tumor volume (mm3) = (length × width × width/2), where length is the longest diameter and width is the shortest diameter. Mice were euthanized at the endpoint, and xenografted tumors were dissected and analyzed.
Clinical tissue sample collection
CRC patients were diagnosed and classified by the Department of Pathology at The Third Xiangya Hospital and Xiangya Hospital according to the World Health Organization guidelines. All surgical specimens were collected in accordance with an Institutional Review Board-approved protocol. All subjects provided written informed consent for entry into this study. Individuals included 92 cases of primary adenocarcinomas with matched adjacent tissue, 22 cases of CRC liver metastasis, 12 cases of CRC lung metastasis, and 23 cases of relapse after 5-Fu + oxaliplatin + leucovorin combination chemotherapy.
Immunohistochemical (IHC) staining
Tumor tissues obtained from CRC patients or xenografts were subjected to hematoxylin and eosin (H&E) staining or IHC staining with specific antibodies. Briefly, the tissue sections were baked at 60 °C for 2 h, deparaffinized, and rehydrated. Slides were submerged into boiling sodium citrate buffer (10 mM, pH 6.0) for 10 min and incubated in 3% H2O2 in methanol for 10 min. Slides were blocked with 50% goat serum albumin for 1 h at room temperature and incubated with primary antibodies overnight in a cold room in a humidified chamber. Slides were washed with PBS, followed by incubation with the secondary antibody for 1 h at room temperature. Hematoxylin was used for counterstaining, which was evaluated independently by two pathologists. The percentage of positive cells was scored as follows: 0, no positive cells; 1, ≤ 10% positive cells; 2, 10–50% positive cells; and 3, > 50% positive cells. Staining intensity was scored as follows: 0, no staining; 1, faint staining; 2, moderate staining; and 3, dark staining. Comprehensive score = staining percentage × intensity. For TRAF4/p-CHK1 expression, a comprehensive score ≤ 1.5 is considered low expression and > 1.5 high expression. The association between TRAF4/p-CHK1 levels and patient clinical features, including age, gender, initial clinical stage, tumor stage, and lymph node status, is summarized in Supplementary Table 4 and Supplementary Table 5. The following antibodies were used for IHC staining: Ki67 (cat. #ab16667, Abcam, 1:250), TRAF4 (cat. #MABC985, Sigma-Aldrich, 1:300), p-CHK1 (cat. #ab47318, 1:200), and CHK1 (cat. #ab47574, 1:100). The Click-iT™ TUNEL Colorimetric IHC Detection Kit (cat. #c10623, Thermo Fisher Scientific) was used for apoptosis detection in tissue sections according to the manufacturers’ standard procedures.
Immunofluorescence (IF)
Cells in a chamber slide were treated with 10 μM 5Fu for 24 h. The cells were fixed with 4% paraformaldehyde and permeabilized in 0.5% Triton X-100 for 20 min, followed by blocking in 5% BSA for 1 h and overnight incubation with γ-H2AX or p-CHK1 primary antibodies at 4 °C in a humidified chamber. Alexa Fluor 488 dye-labeled anti-rabbit IgG was used as the secondary antibody. Nuclei were counterstained with DAPI (cat. #P36935, Thermo Fisher Scientific). For measuring chemotherapeutic agent-induced γ-H2AX or p-CHK1, cells were seeded onto a chamber slide and treated with the drugs overnight. The chemotherapeutic agent-free medium was then added to the chamber slide, and the cells were fixed at various time points (0, 24, or 48 h) as indicated. The following antibodies were used for IF: γ-H2AX (cat. #ab11174, 1:100), p-CHK1 (cat. #ab47318, 1:200), α-tubulin (cat. #ab7291, 1:100), γ-tubulin (cat. #ab11317, 1:100), goat anti-rabbit IgG Alexa Fluor 488 (cat. #ab150077, 1:500), goat anti-mouse IgG Alexa Fluor 488 (cat. #ab150117, 1:500), and donkey anti-rabbit IgG Alexa Fluor Dye 647 (cat. #ab150075, 1:500).
Statistical analysis
Statistical analyses were performed using SPSS (version 16.0 for Windows, SPSS Inc., Chicago, IL, USA) and GraphPad Prism (GraphPad 7.0, San Diego, CA, USA). All quantitative data are expressed as the mean ± standard error of the mean (s.e.m) from 3 independent experiments. Differences between means were evaluated with Student’s t test or analysis of variance (ANOVA). The clinicopathologic significance of clinical samples was evaluated with a χ2 test or a Fisher exact test for categorical data. The Mann–Whitney U test was used when the data did not fit a normal distribution. Kaplan–Meier analysis and the log-rank test (Mantel–Cox) were used for survival analysis. Pearson rank correlation was used for correlation tests. The Wilcoxon matched-pair signed-rank test was used for evaluating expression differences between tumors and adjacent non-cancerous tissues. A probability value of p ≤ 0.05 was used as the criterion for statistical significance.
Discussion
DDR signaling is orchestrated by the ATM–CHK2 pathway, which is activated by double-strand DNA breaks (DSBs), and the ATR-CHK1 pathway, which is activated by tracts of single-strand DNA (ssDNA). DSBs activate not only ATM, but also ATR as the processing of DSBs generates replication protein A-coated ssDNA and recruits ATR. ATR then subsequently phosphorylates and activates CHK1 [
25]. CHK1 activation is largely regulated through post-translational modification, including phosphorylation and ubiquitination [
26,
27]. Phosphorylation not only activates CHK1, but also promotes its K48-linked ubiquitination and degradation after prolonged replication stress [
14,
15]. The E3 ligases cullin 1, cullin 4, and F box protein 6 ubiquitinate and degrade CHK1 to terminate its activity, whereas deubiquitination of CHK1 by USP1, USP7, and ATX3 reverses this termination [
14,
28‐
30]. In contrast to K48-linked ubiquitination that promotes target degradation, K63-linked ubiquitination serves as a molecular platform for protein–protein interaction, which is required for kinase activation, protein trafficking, receptor endocytosis, and DNA damage repair [
31]. Accumulating evidence suggests a critical role of K63-linked polyubiquitination in the regulation of kinase activation. The E3 ligase TRAF6-, TRAF4-, and Skp2-mediated K63-linked ubiquitination of AKT is required for AKT activation in human cancer cells [
16,
32‐
34]. Skp2-dependent ubiquitination and activation of LKB1 in hepatocellular carcinoma cells is essential for cancer cell survival under energy stress [
35]. Furthermore, Skp2 catalyzes K63-linked ubiquitination of NBS1, promoting for the interaction between NBS1 and ATM and thereby facilitating ATM recruitment to the DNA foci for activation [
36]. In this study, we show that in response to the DDR, CHK1 ubiquitination on K132 is catalyzed by TRAF4, which is required for CHK1 chromatin association, ATR binding, and subsequent phosphorylation and activation. CHK1 phosphorylation and activation by ATR are blocked in TRAF4-deficient CRC cell lines. Importantly, TRAF4 deficiency significantly decreases the proliferation, colony formation, and tumorigenesis of cancer cells under treatment with chemotherapeutic agents.
Previous reports showed that CHK1 chromatin association and activation are regulated dynamically and cell- and context-specific. For example, in 293T cells, SPRTN proteolysis releases CHK1 from the sites of replicative chromatin at the S stage during DNA replication [
37]. However, in U2OS cells, DNA damage-induced a PIKK-dependent release of CHK1 from chromatin [
38]. Phosphorylation of S317, but not S345, is required for CHK1 disassociation from chromatin in DDR [
39]. In this study, we show that TRAF4-mediated CHK1 K132 ubiquitination is critical in CHK1 chromatin binding and ATR-induced phosphorylation. Furthermore, we show that CHK1 ubiquitination by TRAF4 is independent of ATR-mediated CHK1 S317/345 phosphorylation, indicating that the K63-linked ubiquitination is required for CHK1 activation at a very early stage of DDR. This is in line with a previous report demonstrating that removing the K63-linked ubiquitination chains by the deubiquitinase USP3 facilitates the disassociation of CHK1 from chromatin after CHK1 phosphorylation by ATR [
40]. These results suggest a novel intermediate step for the well-established ATR-CHK1 signaling during the DDR: TRAF4 ubiquitinates CHK1 on K132, which is a prerequisite for CHK1 phosphorylation and activation by ATR (Fig.
7m).
TRAF4 is overexpressed in many cancer types [
41,
42]. As an E3 ligase, TRAF4 can either degrade or activate targets through different ubiquitination linkages [
16‐
18]. TRAF4 catalyzes K48-linked ubiquitination of SMURF2 to downregulate SMURF2 and promote breast cancer metastasis [
17]. TRAF4 mediates K63-linked ubiquitination of AKT to stimulate AKT membrane recruitment and activation [
16]. In addition, K27- and K29-linked ubiquitination of TrkA, a neurotrophin receptor tyrosine kinase, by TRAF4 increases TrkA kinase activity to enhance prostate cancer metastasis [
18]. The present study identifies CHK1 as a novel substrate of TRAF4 that participates in the DDR and pro-survival signaling in multiple cancer cells by orchestrating K63-linked ubiquitination of CHK1. This work significantly expands our understanding of the substrates and functions of TRAF4 in DDR and cancer cell survival. An adaptor protein BTG3 and E3 ligase CRL4
Cdt2 were recently identified to regulate CHK1 ubiquitination [
13] in different ways from TRAF4. First, TRAF4 knockdown causes a larger reduction in CHK1 ubiquitination than BTG3 knockdown [
13]. Second, BTG3 acts as a tumor suppressor that is required for CHK1 ubiquitination and maintaining genomic stability. In contrast, high expression of TRAF4 enhances CHK1 activation and confers cancer cell chemoresistance, which suggests that TRAF4 functions as an oncogene. Finally, K132 in CHK1 is identified as a conserved residue that is ubiquitinated by TRAF4 in multiple cell lines; however, there is minimal evidence that CRL4
Cdt2 catalyzes CHK1 ubiquitination at this site.
Most chemotherapeutics induce the DDR and apoptotic cell death. 5-Fu inhibits thymidylate synthetase, reducing the size of the available dNTP pools and therefore increasing the stalling of replication forks. Topoisomerases control DNA supercoiling and entanglement by catalyzing nicking and re-ligation of DNA strands. Topoisomerase inhibitors like irinotecan form a complex with topoisomerases and DNA, physically hindering ongoing replication forks and eventually causing cell death [
43]. It is widely believed that cancer cells maintain a proficient checkpoint system, including the ATR-CHK1 pathway, which, upon DNA damage-based therapies, halts cell cycle and allows DNA repair, thus promotes cell survival and confers therapeutic resistance [
44]. The balance between DNA repair and cell apoptosis determines whether cancer cells live or die after chemotherapy. Checkpoint kinases play pivotal roles in maintaining this balance. Suppression of CHK1 in cancer cells impairs the DDR and DNA repair, which eventually potentiates the cell-killing effect of chemotherapeutic drugs [
26], enhances the anti-tumor effect of PD-L1 blockade, and augments cytotoxic T-cell infiltration in vivo [
45]. On the other hand, hyperactivation of ATR-CHK1 signaling confers chemotherapeutic resistance in multiple tumor models [
7,
46,
47]. CHK1 inhibitors, including prexasertib and MK-8776 [
48,
49], are currently in clinical trials alone or in combination with cytotoxic agents, such as cisplatin, pemetrexed, 5-Fu, and gemcitabine, to treat both solid tumors and hematological malignancies [
11,
50‐
55]. In this study, we show that CHK1 phosphorylation positively correlates with TRAF4 in 5-Fu-resistant CRC cells and in relapsed CRC samples. TRAF4 drives chemoresistance, primarily through CHK1 activation in a ubiquitination-dependent manner in CRC cells. In TRAF4-deficient CRC cells, CHK1 is not phosphorylated or activated by 5-Fu treatment, which results in impaired chromosome alignment, increased premature mitosis, and polyploidy. In contrast, in TRAF4 proficient CRC cells, blocking CHK1 ubiquitination with a K132R mutation sensitizes CRC cells to chemotherapy in vitro and in vivo. In addition, the combination of a CHK1 inhibitor and 5-Fu enhances chemotherapeutic-induced cell death and attenuates xenograft tumor development.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.